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From the Editor’s Desk
This issue’s goal is to impart transplant related
information to health care providers in a readable,
understandable format that will not become
outdated anytime soon. Focusing on this, we have
strived to compile topics that cover the spectrum
of basic knowledge, important investigations,
clinical conditions and newer techniques in the
field of transplantation. Continuing the quest
for knowledge while keeping the interest alive,
this issue therefore contains broad variety of
topics on Haemopoietic stem cell and kidney
transplantation.

Transplant medicine is complex and
multidisciplinary. Accordingly, the articles in this
issue are on pretransplant evaluation, significance of
HLA typing, blood product utilization in transplant
recipients, monitoring of immunosuppressive
therapy and infections in neutropenic patients
to name a few. This diversity of articles has
been carefully created so that our readers find it
appealing and useful to the utmost level.
Dr Natasha Ali
Hematology

Significance of HLA Typing in Transplant
Medicine
Nazneen Islam and Afsheen Ibrahim
Molecular Pathology

Introduction

5) Population genetics of the HLA system

The major Histocompatibility Complex (MHC) is a
group of genes located on short arm of Chromosome
number six (6p21.3). In humans, the MHC gene
products are called human leukocyte antigens
(HLAs). This region contains 200 genes, many of
Figure 1. The MHC locus on chromosome 6 covers about 4 Mb of DNA,
which involve in immune responses. The genes
depending on the individual. Class I genes are 3-6 kb long and class
II genes are 4-11 kb in length. TNF-α and TNF-β are not part of the
encode the HLA Class I (A, B,C) and Class II (DR,
polymorphic HLA system.
DQ, DP) molecule (Figure1). The essential role of
the HLA antigens is the initiation and regulation
of the immune response(Table 1).
Table 1. Description of MHC Class I& Class II locations and function
The physiologic function of MHC
MHC Region
Gene Products
Tissue Location
Function
molecules is the presentation of
peptide antigen to T lymphocytes
Class I
HLA-A, HLA-B,
All nucleated cells
Identification and
HLA-C
destruction of
and distinguishes “self” from “nonabnormal or infected
self. The clinical utility of HLA
cells by cytotoxic T
typing in following purposes:
cells

1) Bone Marrow Transplantation
2) Solid organ Transplantation
3) Transfusion Medicine
4) Marker of Autoimmune diseases

Class II

HLA DR, HLA
DQ, HLA DP

B lymphocytes,
Identification of
foreign antigen by
monocytes,
macrophages,
helper T cells
dendritic cells,
activated T cells,
activated endothelial
cells, skin
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HLA and Transplant Immunity
Histocompatibility molecules of one individual act as
antigens when introduced into a different individual
in organ transplantation. Mismatched HLA antigens
can stimulate B cells to produce alloantibodies,
which are involved with humoral mechanisms of
transplant rejection, Class I antigens controlled by
the HLA-A, -B and -C loci are the primary targets of
alloantibodies, studies also indicates that antibody
reactivity to class II antigens encoded by HLA-DR
and HLA-DQ antigens may also result in graft loss.
Table 2. Potential effects of human leukocyte antigen (HLA)
on transplant immunity
Humoral Immunity
 Against Class I HLA antigens
 Complement-dependent antibodies
 Complement-independent antibodies
 Against Class II HLA antigens
 Cellular Immunity
 Direct allorecognition
 Cytotoxic CD8 T-cells
 Effector CD4 T-cells
 Regulatory T-cells
 Indirect allorecognition
 Effector CD4 T-cells
 HLA-Restricted Immune Responses
 Antiviral immunity
 Cytotoxic CD8 T-cells
 Recurrent autoimmune disease
 Effector CD4 T-cells


Table 3. HLA matching protocols for kidney transplantation
Matching for HLA-A, -B, and -DR Antigens
Mismatching for HLA-A, -B, and -DR antigens
 Broad vs split antigens
 Acceptable and unacceptable mismatches for highly
sensitized
 Candidates
 Permissible mismatches with graft outcome similar to
on-mismatched transplants
 DR Matching
 CREG Matching
 Public and private class I epitopes
 Structurally Based Matching
 Amino acid residue mismatching
 HLA Match maker



Abbreviations: HLA human leukocyte antigen; CREG cross-reacting
groups of antigens
Reference: American Society for Histocompatibility and Immunogenetics,
2004

4

Clinical Reality of HLA Matching, Graft Survival
and Outcome
HLA matching significantly reduces the risk of
graft rejection and graft failure after solid-organ
transplantation and graft-versus-host disease (GvHD)
after hematopoietic stem-cell transplantation.
For example in kidney transplantation, current
criteria for HLA matching consider three loci:
HLA-A, HLA-B and HLA-DR Many studies have
shown the superior results with zero HLA-A, B, DR
mismatches which expand longer allograft halflives (12.5 versus 8.6 years) and increased 10-year
survival (52 versus 37 per cent). However in bone
marrow and stem cells transplantation the donor’s
and recipient’s HLA tissue types match plays a large
part in survival. A match is better when all 5 of the
known major HLA antigens are the same as five out
of five match.
Table 4. Confounding factors for Kidney Transplant
Quality of Donor Kidney
 Donor age: expanded criteria donors
 Extended ischemia time
 Living donors
 Recipient Risk Factors
 Pediatric recipients
 Ethnicity
 Sensitization
 Immunosuppression


Molecular Analysis of HLA Typing
Various molecular methods have been evolved for
HLA DNA typing. PCR SSP i.e. Sequence specific
Primer based PCR is one of the reliable method
because among them. PCR-SSP methodology is
based on the principle that completely matched
oligonucleotide primers i.e. HLA-A, B, C, DR and
DQ alleles. Primer pairs are designed to be matched
with single alleles or group(s) of alleles depending
upon the degree of typing resolution required.
Completely matched primer pairs allow amplification
to occur, i.e. a positive result, whereas mismatched
primer pairs doesn’t allow amplification to occur, i.e.
a negative result (Figure 3). After the PCR process,
the amplified DNA fragments are size-separated
e.g. by two per cent agarose gel electrophoresis,
visualized by staining with ethidium bromide
and exposure to ultraviolet light, documented by
photography and interpreted. Interpretation of PCRSSP results is based on the presence or absence of
specific PCR product(s) (Figure 4).
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DNA
DN

Mismatched

Matched

Internal controls
Allele-specific product
No Amplification

Amplification

Figure 3. Principle of PCR-SSP. Allele-specific product only from those wells containing primers matching the specimen HLA allele. Wells containing
primers that do not match the patient’s HLA allele will have a band only from the internal control.

Beta globin internal control

Positive Amplification Band

Result Interpretation:
 After Electrophoresis gel photograph are
examined and positive lanes determine carefully
 An internal positive control band, should be
visible in all gel lanes, except in the negative
control gel lane, as a control of successful
amplification. The internal positive control band
may be weak or absent in positive gel lanes.

Figure 4. Gel electrophoresis of HLA Typing SSP
Ref: Olerup, Micro SSP HLA-A, HLA-B, HLA-C plate
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Role of Protocol Renal Biopsies in Transplant
Patients
Drs Sidra Arshad and Saroona Haroon
Histopathology
Renal transplantation has become the treatment of
choice for patients with end-stage renal disease.
Protocol biopsies early after transplantation have
detected subclinical disease, which has excited
clinical investigators and prompted them to consider
this as a potential surrogate marker for evaluating
transplantation outcome.

nephrotoxicity, allowing modifications of
therapy to limit ongoing graft injury
When to Perform?





Implantation biopsy (donor biopsy):
Individual zero time biopsies have been
shown to correlate with the graft outcome





Indication biopsy: Dysfunctional allograft
biopsy and allograft biopsy for proteinuria

Optimum timing of surveillance biopsies depends
on the pathology. Biopsies up to three months from
transplant show a higher frequency of SCR with a
greater incidence of IF/TA beyond six months and
presentation of recurrent and de novo GN, TG and
CNI toxicity occurring at various time points from
transplantation. Early surveillance biopsy yields
the greatest reversible pathology while biopsies
beyond one year serve as prognostic indicators of
graft survival and help tailor immunosuppression
according to the individual.





Protocol biopsy

Preparation of the Biopsy for Evaluation

Types of Renal Allograft Biopsies

Protocol Renal Biopsy
It is performed at pre-determined intervals after
transplantation in normal functioning allografts.
Aided research and provided insights into the
pathogenesis of early and late allograft injury.
Role in Clinical Practice




Detection of subclinical rejection (SCR)





Individualization of therapy in high-risk
patients and safe reduction of
immunosuppression in standard risk
individuals becomes possible





Chronic T cell or antibody-mediated
rejection





Recurrent or de novo glomerulopathies





Viral nephropathy





Interstitial fibrosis/ Tubular atrophy(IF/TA)





Chronic calcineurin inhibitor(CNI) -

6

The biopsy should be processed and prepared
according to the renal transplantation guidelines
for allograft biopsy handling by an experienced
technologists. Allograft biopsies are processed by the
rapid method using auto processor and are reported
on the same day. According to Banff scheme, it is
recommended to prepare at least seven slides(3-4
microns thick), with multiple sections mounted on
each slide. Three of these should be stained with
hematoxylin and eosin (H&E), three with periodic
acid-Schiff reagent (PAS) and one with a Masson’s
trichrome stain.
Pathological Evaluation
The accurate pathologic evaluation of renal
allograft biopsy requires a well-trained renal
pathologist with a thorough knowledge of renal
transplant pathology, and also of renal and
transplant medicine in order to correlate the
morphologic abnormalities with the detailed
clinical information. The importance of
correlation of morphological findings on the
renal allograft biopsy with clinical data and a
close interaction between the nephrologists and
pathologists is no doubt of great significance.
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Role of Special Stains and other Ancillary
Studies
The PAS and/or silver stains are very useful
in delineating tubular basement membranes
(TBMs) and in defining the severity of tubulitis,
and for evaluating glomerulitis. The PAS stain
is also useful in the identification of arteriolar
hyalinosis, tubular atrophy and their semiquantitative scoring. Trichrome stains help
in assessing the chronic sclerosing changes
in the interstitium and in the arterial intima.
C4d antibody is performed to rule out humoral
rejection process.

Future Recommendations
While renal biopsy remains the current “gold
standard “for investigation and assessment
of allograft pathology, development of either
supplementary molecular methods or minimally
monitoring or noninvasive monitoring has
to be expanded. The cost, risk and patient
inconvenience of surveillance biopsies must
be weighed against potential gains from early
interventions guided by the findings. These
biopsies have provided marked insights into the
subclinical processes affecting the graft with
implications for the long term graft outcome.

Umbilical Cord Stem Cells
Dr Natasha Ali
Hematology

In the developed world, haematological malignancies
account for 10 percent of new cancer diagnosis.
Many of these malignancies can be cured with
chemotherapy alone. However, most of the time
chemotherapy alone is not enough to achieve a
cure and these patients then require haemopoietic
stem cell transplantation (HSCT). HSCT provides
curative therapy for a variety of diseases. Every
year more than 30,000 patients with haematological
malignancies receive high dose chemotherapy
followed by HSCT. The stem cells used in the
procedure can be obtained from bone marrow;
G-CSF mobilized peripheral blood and cord blood.
Despite this, the availability of a match related donor
still remains to be limited.
Umbilical cord blood availability as a prospect for
therapeutic use was first reported in Lancet in 1939.
It was not until 1970s when the medical brothers
Ende published the transplantation of multiple
units of umbilical cord blood into an individual3.
Although this procedure was not successful due
to the multiple disparities of the transplant unit,
it did pave a way to investigate cord blood on a
more serious level. In 1988 eventually, successful
transplant of a patient with Fanconi’s anaemia was
performed and published in 19894. The possibility
to use one of the largest cellular sources available,
but normally discarded, was an exciting move which
led to umbilical cord blood stem cells being used

Table 1. (Adapted from - The Journal of Perinatal Education,
20(1), 54-60, doi: 10.1891/1058-1243.20.1.54)

Advantages of Umbilical Cord Blood Stem Cells
Versus Bone Marrow Stem Cells
 Ease of collection
 No risk for mother or child
Less time needed for processing (more quickly available
for use)
Less costly than bone marrow collection
Less risk for transmission of infection
Less need for stringent antigen typing
Less rejection
Table 2: (Adapted from - The Journal of Perinatal Education,
20(1), 54-60, doi: 10.1891/1058-1243.20.1.54)

Disadvantages of Umbilical Cord Blood Stem Cells
Slow engraftment
Limited cell dose
Small volume of unit
Additional cell doses unavailable
Autologous donation may have limited benefit
  owing to hereditary disorders
Storage issues
Unknown length of long-term storage
Cost related to long-term storage
Quality control

to treat a variety of malignant and non-malignant
haematological disorders. Umbilical cord stem cells
present a number of advantages over bone marrow
stem cells (Table 1).
7

VOL. 40, ISSUE 2

NOVEMBER 2014

However, like all therapies, it is associated with
caveats (Table 2)
These stem cells are stored in stem cell banks
after donation. There are three types of umbilical
cord blood banks; private, public and directdonation banks. Private Banks are commercial
that promulgate directly to expectant parents.
Private Banks charge an initial fee for collection
and processing and a yearly fee for storing the
specimen. Public umbilical cord blood banks accept
altruistic donations. Donated units are processed,
antigen typed and stored for future use. Direct
donation banks function as an amalgamation of
public and private cord blood banks. They collect

cord blood without charging fees. In addition, they
accept autologous donations and reserve them only
for the family.
Umbilical cord blood, once thought of as a waste
product of the birthing experience, is now valued
for its content of stem cells. Saving cord blood is
a worthy undertaking for any family. Obstetricians
and haematologists are one of the first resources
that an expectant family turns to for knowledge in
order to reach an informed decision about collecting
umbilical cord blood. Therefore, we as physicians
should be well versed on the topic, so that as
questions arise, the multiple facets of umbilical
cord blood banking can be explored.

Blood Product Utilization in Haematopoietic
Stem Cell Transplant Recipients
Dr Hira Qadir
Haematology

Introduction
Hematopoietic stem cell transplant (HSCT)
patients often require intensive blood component
support. Transfusion may be complicated by
transfusion transmitted infection- both viral and
bacterial, transfusion-associated (TA)-GvHD,
febrile non-hemolytic transfusion reactions
(FNHTR) and transfusion-related acute lung injury
(TRALI). Alloimmunization to red cell antigens
may cause difficulties in selecting compatible
blood while alloimmunization to the human
leukocyte antigens (HLA) present on platelets may
cause refractoriness to subsequent transfusions of
randomly-selected platelets.

are HLA incompatible. This is clinically manifest
as a failure to achieve a satisfactory increment
after platelet transfusion (refractoriness). Donor
dendritic cells which are present in red cell and
platelet transfusions appear to be responsible for
sensitization to HLA. Studies show that removal
of leukocytes to less than 5 x 106 per blood
component prevents primary HLA-A1 in >97 per
cent of patients with hematological malignancies.
The use of leukodepleted components also reduces
secondary A1 and refractoriness to platelet
transfusion.
Indications for Leukodepleted Blood Components


Pre-HSCT in patients with severe aplastic anemia
(SAA) to reduce the likelihood of graft failure



Pre- and post-HSCT to prevent recurrent FNHTR



Pre-and post-HSCT to minimize HLA-A1 and
platelet refractoriness

Leukodepleted Blood Components
Transfused leukocytes cause alloimmunization to
HLA Class one antigens (HLA-A1) in a proportion
of patients. This may be manifested clinically
as FNHTRs, although these may also be caused
by antibodies to neutrophils, platelets or plasma
proteins and by cytokines such as interleukin
(IL)-1, IL-6, IL-8 and tumor necrosis factor which
accumulate in stored blood components, especially
platelet concentrates. HLA-A1 may cause
accelerated destruction of transfused platelets that
8

Many Blood Services have implemented
leukodepletion of a large proportion or, in some
cases, all of their blood components. In the UK
universal leukodepletion was implemented in 1999
with the aim of minimising the risk of transfusion
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associated transmission of the causative agent of
variant Creutzfeld-Jakob disease (vCJD); As an
alternative to CMV seronegative components.
Gamma-Irradiation of Blood Components and
TA-GvHD
HLA incompatible third party leukocytes contained
in donated blood components can engraft and
initiate an alloreactive response after transfusion.
This can cause TA-GvHD, manifest clinically by
fever, rash, diarrhea, jaundice and pancytopenia,
and this is fatal in >90 per cent of cases, so
prevention is essential. Donor leukocytes are
inactivated by gamma-irradiation of 2500 cGy
and all components for HSCT recipients should be
irradiated from the time that conditioning therapy
is started and continued until six months posttransplant or until the lymphocyte count is 1 x
109/L in the absence of chronic GvHD. In addition,
HLA matched packed red cells should be irradiated,
as should those from family members.
Indications for Irradiated Blood Components
Allo-HSCT recipients from time of conditioning
therapy for 6 months or until the lymphocyte
count is 1 x 109/L in the absence of cGvHD


Auto-HSC recipients (from 7 days before harvest
until 3 months post transplant)



All donations from HLA-matched donors or 1st or
2nd degree relatives



All patients with Hodgkin disease at any stage of
therapy



All patients treated with purine analogues e.g.
fludarabine



All patients with congenital immunodeficiency
states

Red Cells
Red cells, are transfused to correct anemia due to
marrow failure, hemorrhage or hemolysis, aiming to
keep the hemoglobin or packed cell volume (PCV)
above predefined levels to ensure good tissue
oxygenation. Reduced intensity conditioning (RIC)
transplants require fewer red cell transfusions.
Red cells should be matched for ABO and Rhesus
D type. Extended phenotyping may be necessary
in patients, e.g. those who have formed red cell
alloantibodies after previous transfusions. Red cells
should be cross-matched against the patient’s serum
by standard techniques prior to transfusion.
Platelet Transfusions
Current practice, based on the results of
randomized studies, is to transfuse platelet
concentrates prophylactically when the platelet
count is less than 10 x 109/L. A recent Cochrane
Systematic Review concluded that, whilst there
is no reason to change current practice, blood
products may become scarcer and further trials
should be undertaken to compare prophylactic
versus therapeutic platelet transfusion.
Conclusion
Transfusion support in HSCT patients requires
special consideration and carefully defined
policies. The use of high quality blood
components which have a high degree of
microbiological safety, gamma-irradiated, may be
CMV seronegative and leukodepleted provides
optimum transfusion support and minimizes the
chance of adverse effects.
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Use of Magic Marker “C4d” in the Diagnosis
of Acute Antibody Mediated Rejection in
Renal Transplant Patients
Dr Muhammad Ishaque and Dr Saroona Haroon
Histopathology

Renal transplantation is the treatment of choice for
patients with end stage renal disease worldwide.
Transplant rejection can be defined as an immune
response of the patient that is activated against
foreign material i.e. graft, which without treatment
leads to the destruction of the graft. There are three
different types of rejection when classified according
to the time of onset.
1- Hyperacute or accelerated rejection usually
occurs during the first hours after transplantation
and leads to the loss of the graft. In most cases it
can be avoided by the pre transplant cross match
test.
2- Acute rejection occurs usually during the first
weeks or months after transplantation occurring
in 40 per cent to 70 per cent of the cases, if
mild rejections are included. It manifests
typically as asymptomatic elevation of serum
creatinine. The diagnosis is confirmed by renal
graft biopsy which shows lymphocytic infiltrate,
tubulitis and edema. Acute rejection usually
responds well to high dose corticosteroid
treatment.
3- Chronic rejection is defined as a gradual but
progressive impairment of renal allograft
which can occur at any time after the initial post
transplantation months. It does not respond well
to antirejection treatment usually leading to the
loss of graft.
In recent years it has been recognized that about
10% of acute rejection cases generally ensuing in
the first three months, are due to donor specific
antibodies, not detected before transplantation.
In most of these cases antibodies are directed
against class I or II HLA antigens, but sometimes
they are directed towards different endothelial
antigens and cannot be detected even with more
advanced tests.
10

That an antibody mediated process is operating in
this type of rejection is testified by the capillary
deposition of C4d, which is a degradation product
of the classic complement pathway. After an
antigen-antibody complex fixes complement,
a cascade of events follows, with activation of
several complement proteins. The complement
protein C4 is split into C4a and C4b. C4b is then
converted to C4d. A unique feature of C4d is that
it binds covalently to the endothelial and collagen
basement membranes, thereby avoiding removal and
raising the possibility of serving as an immunologic
footprint of complement activation and antibody
activity. In 2003 ‘C4d’ was incorporated in the Banff
classification.
Together with the serologic evidence of
circulating antibodies to donor HLA antigens or
to other donor endothelial antigens that were not
present at the pre-transplant cross-match, two
cardinal morphologic features are needed for the
diagnosis:
1)

Evidence of acute tissue injury such as:
(a) acute tubular necrosis;
(b) neutrophils and/or monocyte-macrophages
in peritubular and glomerular capillaries and/
or capillary thrombosis or
(c) fibrinoid necrosis/transmural inflammation
of arteries

2) Immunopathologic evidence of an antibody
action, such as:
(a) C4d complement and/or immunoglobulins in
peritubular capillaries, or
(b) immunoglobulin and complement in arteries
with transmural fibrinoid necrosis.
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product C4d in renal live related allograft biopsies is
an important adjunctive tool to help understand the
alloimmune response and, in particular, to diagnose
antibody-mediated rejection (AMR). In patients with
this form of rejection, renal insufficiency develops
briskly but sometimes insidiously. Although a rescue
treatment with new potent immunosuppressive
agents and plasma exchange may be successful in
some cases, the one year graft-loss ranges from 25
per cent to 50 per cent. C4d is now one of the core
diagnostic tools to identify AMR, and is being used
in virtually all transplant centers around the world.

If transplantation has occurred greater than one
year from the time of the biopsy, the likelihood of
recurrence of a native kidney disease is increased.
For this reason, a full work-up like that seen for a
native kidney biopsy is recommended. This includes
light microscopic, immunofluorescent, and electron
microscopic analysis plus C4d. C4d by the indirect
immunofluorescence approach is a more sensitive
than monoclonal antibody staining, it is performed
on the frozen section tissue.
C4d is detectable in the glomerular mesangium
and at the vascular pole of the normal kidney. This
emphasizes that there is constitutive turnover of
immune complexes. When the burden of immune
complexes increases with immune complex
deposition diseases, C4d deposition overflows from
the mesangium and vascular pole to the glomerular
capillaries. In transplanted kidneys, Donorspecific antibody (DSA) directly engages human
leukocyte antigens (HLAs), which are present in the
glomerulus as well as the peritubular capillaries. It is
known that anti-complement protection in the PTCs
is weaker than in the glomerulus (Figure 1).
Hence detection of the complement split

The difficulties of interpreting focal staining patterns,
the relatively low sensitivity of C4d as a marker
for AMR in late renal allograft biopsies, and its
lack of utility as a marker for antibody-mediated
injury in biopsies of ABO-incompatible allografts
suggest that C4d has lost some of its magic during
the past decade. However, most experts come to an
understanding that if complement targeted therapies
will be part of our future treatment options; a marker
such as C4d will still be obligatory to identify
patients susceptible for those kinds of expensive
treatments.

Patient:
14 days after tx
rapid rise
in creatinine

A definite diagnosis of acute antibodymediated rejection requires:
or

Histological
features,
‘suspicious’ for
acute AMR:
Type 1: ATN-like
minimal inflammation
Type 2: peritubular
capillaritis, glomerulitis,
or thrombosis
Type 3: arterial
fibrinoid necrosis

Immunohistochemistry

Immunofluorescence

Presence of
donor-specific
antibodies
against:

C4d deposition in peritubular
capillaries
Diffuse
(>50% ptc)

Focal (>1050% ptc)

Minimal or
absent
(0-10% ptc)

Consider
positive

Consider
positive when
performed by
immunohistochemistry

Consider
negative






Donor-specific
HLA molecules
Blood group
antigen (ABO)
isoagglutinins
Endothelial cell
antigens

Source: Kidney Int © 2012 Inernational Society of Nephrology

Figure 1. Donor specific antibodies engaging with human leukocyte antigen
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Assessing Post Transplant Renal Function
Dr Lena Jafri
Chemical Pathology

Identifying kidney allograft dysfunction as soon
as possible will permit timely diagnosis and
management. Monitoring allograft function includes
direct and indirect measurement of glomerular
filtration rate (GFR) and quantitation of urinary
protein excretion besides the invasive and various
radiological tests available.
Serum Creatinine
The standard test used to monitor graft function is
serum creatinine measurement. Creatinine is derived
from the metabolism of creatine in skeletal muscle
and from dietary meat intake. It is released into the
circulation at a relatively constant rate. Creatinine is
freely filtered across the glomerulus and is neither
reabsorbed nor metabolized by the kidney. However,
approximately 10-40 per cent of urinary creatinine is
derived from tubular secretion by the organic cation
secretory pathways in the proximal tubule. Increased
serum creatinine post-kidney transplant that is not
explained by dehydration, urinary obstruction, high
calcineurin inhibitor levels or other apparent causes
is most likely due to an intragraft parenchymal
process, such as acute rejection, chronic allograft

injury, drug toxicity, recurrent or denovo kidney
disease.
Following is the diagnostic criteria for acute
kidney injury: an abrupt (within 48 hour)
reduction in kidney function currently defined as
an absolute increase in serum creatinine of ≥ 0.3
mg/dL, a percentage increase in serum creatinine
of ≥ 50 per cent (1.5-fold from baseline), or a
reduction in urine output (documented oliguria
of less than 0.5 mL/kg/hour for more than six
hour). This criteria includes both an absolute and
a percentage change in creatinine to accommodate
variations related to age, gender and body mass
index, and to reduce the need for a baseline
creatinine but do require at least two creatinine
values within 48 hour.
The serum creatinine concentration however is
an indirect measurement of GFR. At low serum
creatinine levels, small changes in creatinine can
indicate large changes in function. It is essential
for clinical laboratories providing transplant
service to keep a strict check on internal quality
controls of serum creatinine and to keep its

Table 1. Formulae for Estimating Glomerular Filtration Rate in adults.

Method of GFR calculation

Formulae

CrCl
(ml/min/1.73m2)

urinary Cr x volume x 1.73/ serum Cr x1440 x BSA

MDRD
(mL/min/ 1.73 m2)

175 x Cr (exp[-1.154]) x Age (exp[-0.203]) x (0.742 if female)

CG
(mL/min)

(140 - age) x weight / serum Cr [mg/dL] x 72 x (0.85 for females)

CKD-EPI
(mL/min)

If Cr < 0.9 (for male): 141 x (Cr/0:9)0. 411 x 0:993Age
If Cr > 0.9 (for male): 141 x (Cr/0:9) -1.209 x 0:993Age
If Cr < 0.7 (for female): 144 x (Cr/0.7)-0.329 x 0:993Age
If Cr > 0.7 (for female): 144 x (Cr/0:9)-1.209 x 0:993Age

Abbreviations: GFR= glomerular filtration rate; CrCl= creatinine clearance; Cr= creatinine; BSA= body surface area; MDRD=
modification of diet in renal disease; exp= exponential; CG= Cockcroft Gault. Serum Cr in mg/dL, weight in kg, height in meters,
age in years, and BSA in meter square.

12
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coefficient of variation within narrow limits
(preferably with ±1SD). The clinical laboratories
must use a creatinine method that has calibration
traceable to an isotope dilution mass spectrometry
(IDMS) reference measurement procedure.
Additionally, patients with small muscle mass
generate less creatinine on a daily basis and
normal levels in such patients may mask allograft
dysfunction in them. The increasing use of
estimated GFR (eGFR) in clinical practice has
renewed the interest on the shortcomings of serum
creatinine alone.
Formulae that Estimate GFR
The most common methods utilized to estimate the
GFR are: measurement of the creatinine clearance;
and estimation equations based upon serum

VOL. 40, ISSUE 1

protein levels are below 500 mg/d. However, even
these low levels are associated with reduced graft
survival. The reason can be the native kidney or
the allograft, probably as a consequence of the
ischemia-reperfusion injury. Proteinuria falls after
successful kidney transplantation within few weeks.
The residual or late proteinuria represents graft
injury. Most allografts with proteinuria >1500
mg/d have new glomerular pathology. Evidence on
proteinuria after renal transplantation shows that
microalbuminuria and more significantly proteinuria
after transplantation are markers of graft dysfunction,
correlated both to graft failure and to cardiovascular
risk indicators. In patients with proteinuria one has to
exclude recurrent glomerulonephritis (refer to Table
2) in order to avoid unnecessary immunosuppression.

The 2009 Kidney Disease: Improving Global
Outcomes (KDIGO) clinical practice guideline
Table 2. Causes of Proteinuria after Kidney Transplantation.
on the care of the kidney
transplant recipient
Allograft Rejection and Drug Toxicity
recommended to measure
Acute rejection
Thrombotic microangiopath
urine protein excretion at
least once within the first
Chronic allograft injury
Transplant glomerulopathy
month after transplantation,
De Novo and Recurrent Glomerular Disease
every three months during
the first year and annually
Minimal change disease
IgA glomerulonephritis
later on. For the new-onset
Focal segmental glomerulosclerosis
Membranous glomerulonephritis
proteinuria or unexplained
nephrotic proteinuria renal
Membranoproliferative glomerulonephritis
Postinfectious glomerulonephritis
allograft biopsy should
Thrombotic thrombocytopenic purpura
Hemolytic Uremic Syndrome
be performed. Proteinuria
and albuminuria can be
Vasculitis
Amyloidosis
quantified with a 24 hour
Light- and heavy-chain deposition disease
Systemic lupus erythematosus
collection or by using spot
urine collections (AlbuminDiabetic nephropathy
Creatinine Ratio (ACR)
or
Protein-Creatine
Ratio
(PCR)). KDIGO suggest
creatinine such as the Cockcroft-Gault equation,
that ACR and PCR are reasonable screening tests
the Modification of Diet in Renal Disease
in the renal transplant recipients. The positive
(MDRD) study equations, and the Chronic Kidney
thresholds for proteinuria have been established
Disease Epidemiology Collaboration (CKD-EPI)
to be >250 (men) or >355 (women) mg/g by ACR
equation. However, none have not been validated
and >200 mg/g by PCR. The KDIGO guidelines
in our population. Out of these equations which
recommend monitoring of proteinuria as part of
were developed for chronic kidney disease
routine transplant follow-up. Any positive screen
patients, the MDRD has been validated in renal
should be confirmed by a 24 hour urine collection.
transplant patients.
Twenty-four hour urine protein excretion is the gold
standard for quantitative protein assessment. If the
Proteinuria
24 hour urine collection is problematic, the urinary
protein/creatinine (mg/g) ratio assessed in‘spot’
The rate of protein excretion in healthy adults
urine is an excellent surrogate, as it has proved
is <150 mg/day, of which less than 30 mg is
to have an excellent correlation with the protein
albumin while the rest comprises different
content of a 24 hour urine collection. The KDIGO
proteins and glycoproteins originating from
also suggest biopsy for unexplained proteinuria
tubular epithelial cells. Proteinuria is common
>3 g/day.
after kidney transplantation and typically urine
13
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Coagulopathy in Renal Transplantation
Dr Anila Rashid
Haematology

Chronic renal failure impairs processes of
hemostasis in complex ways. Accumulation of
protein biodegradation products disturbs platelet
production and function, resulting in a hemorrhagic
diathesis. The bleeding tendency is increased by
vascular defects and deficiency of clotting factors
II, V, IX, and X (Figure 1). On the other hand, high

Successful kidney transplantation does not result
in complete regression of hemostatic disturbances.
There are several factors relevant in the periand post-transplant periods known to influence
the coagulation process, such as the function
of the kidney, the immune response, and the
immunosuppressive agents used post-transplantation.

Figure 1. Factors involved in increased risk of bleeding in patients with renal failure and transplant.

concentrations of fibrinogen as well as VII and XIII
clotting factors in uremic patient plasma increase the risk
of thrombosis. Thrombus formation is not controlled
by clotting inhibitors, because of impaired activity of
antithrombin III, heparin cofactor II, as well as proteins
C and S. Additionally, injury to vascular endothelium
stimulates production of factor VIII and von Willebrand
factor. Finally, decreased plasma fibrinolytic activity is
observed in uremic patients (Figure 2).
14

Bleeding is the most common early complication
after transplant (6.1per cent-8.3 per cent). It concerns
mainly platelet function and clotting inhibitor
activities.
A hematoma in the kidney graft area is usually
caused by bleeding from tiny vessels in the renal
hilus that are constricted during the operation, and
begin to bleed after improved graft perfusion. The
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Figure 2. Factors involved in increased risk of thrombosis in patients with renal failure and transplant.
Source: Lutz J et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014 Jan;29(1):29-40.

origin of the bleeding can be bladder wall vessels;
vascular anastomosis leaks; kidney graft rupture;
or a spurious aneurysm due to an infected arterial
anastomosis. The risk of bleeding is increased
by perioperative antithrombotic and antiplatelet
treatment. Hemorrhagic complications requiring
surgical intervention significantly increase the risk of
transplanted kidney loss.
Arterial thrombosis develops in 0.5 per cent to 3 per
cent of transplanted kidneys. Renal vein thrombosis
is observed in 0.5 per cent to 4per cent patients.
The reason for thrombosis in the early postoperative
period is usually a technical failure: torsion
or kinking of the vessel, an overly too narrow
anastomosis, or injury to the endothelium.
Other reasons can be cardiac arrest, persistent
hypotension, acute rejection, diabetes mellitus,
thrombophilia, and later, glomerulonephritis, posttransplant erythrocytosis or the side effects of an
immunosuppressive drug, particularly cyclosporine.
Since the transplanted kidney does not possess a

collateral circulation, arterial or venous thrombosis
usually results in graft loss despite immediate
surgical intervention.
Routine hematologic assessment of all transplant
candidates includes a complete blood count,
measurement of partial thromboplastin time,
prothrombin time, International Normalized Ratio
(INR), fibrinogen and D-dimer concentration.
Patients with recurrent miscarriage, arterial/venous
thrombosis, hemodialysis graft or fistula thrombosis,
or prior unexplained graft thrombosis should be
evaluated for underlying hypercoagulable state like
lupus anticoagulant, acquired inhibitors, inherited
thrombophilia and may require anticoagulation therapy
in the perioperative period. Patients with bleeding
tendencies should have additional coagulation studies
like bleeding time and platelet function test.
Transplant physician along with hematologist should
search for the risk factors both in pre- and posttransplant period in order to detect high risk patients
and apply suitable prophylactic measures.
15
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Post Renal Transplant Erythrocytosis
Dr Maria Shafiq
Haematology

Post-transplant erythrocytosis (PTE) is defined as
persistently elevated hemoglobin and hematocrit
levels that occur following renal transplantation and
persist for more than six months in the absence of
thrombocytosis, leukocytosis, or another potential
cause of erythrocytosis.
The threshold hematocrit used to define PTE is
variable and ranges between 51 to 54 per cent;
most clinicians use 51 per cent (corresponding to a
hemoglobin concentration of approximately 17 g/dL).
The following hormonal systems and growth factors
have been implicated in the pathogenesis of PTE:


Erythropoietin



Hematopoietic growth factors such as
insulin-like growth factor-1 and its binding
proteins and serum-soluble stem cell factor



Renin-angiotensin system



Endogenous androgens

Even among PTE patients with serum erythropoietin
concentrations within normal range, the

concentration may be inappropriately elevated for
given haemoglobin.
Diagnostic evaluation includes the exclusion of
renovascular hypertension or underlying malignancy
and, in selected patients, an evaluation for chronic
obstructive pulmonary disease (COPD).
The preferred initial treatment for patients with
PTE who have a hemoglobin concentration <18.5
g/dL is an angiotensin receptor blocker (ARB) or
angiotensin converting enzyme (ACE) inhibitor,
since these agents are effective in the majority of
patients, are reasonably safe, and, among many
patients, provide a necessary antihypertensive effect.
Theophylline may be effective in some patients who
cannot take ACE inhibitors or ARBs and for whom
repeated phlebotomy is unacceptable. Alteration
of the immunosuppressive regimen to include
antiproliferative agents may be effective in treating
PTE but is rarely done in the absence of other
indications.
For patients who present with hemoglobin >18.5 g/dL,
therapeutic phlebotomy is recommended in addition
to an ARB or ACE inhibitor. For patients who do
not respond to ARBs or ACE inhibitors, intermittent
phlebotomy is suggested rather than other therapies.

Therapeutic Drug Monitoring of Cyclosporine
Dr Sibtain Ahmed
Chemical Pathology

Cyclosporine is acyclic peptide composed
of 11aminoacids. Discovered in the lab of
Sandoz in Switzerland in 1972, cyclosporine
has since revolutionized transplant medicine.
It is a selective immunosuppressant agent.
In the cytoplasm, cyclosporine binds to its
immunophilin, cyclophylin forming a complex.
The cyclosporine-cyclophylin complex binds
and blocks the function of the enzyme a
16

calcineurin, which has a serine/threonine
phosphatase activity. As a result, calcineurin
fails to dephosphorylate the cytoplasmic
component of the nuclear factor of activated T
cells, and thereby the transport of activated T
cells to the nucleus. Consequently, T cells do
not produce IL-2, which is necessary for full
T-cell activation. Therefore it inhibits T cell
activation.
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Cyclosporine is indicated for the prophylaxis of
organ rejection in kidney, liver, heart and bone
marrow transplants. The drug may also be used in the
treatment of chronic rejection in patients previously
treated with other immunosuppressive agents.
It is also used for the treatment of autoimmune
conditions, such as rheumatoid arthritis and psoriasis
to ease symptoms. Cyclosporine presents some
pharmacokinetic features listed below that make
therapeutic drug monitoring imperative:


Narrow therapeutic index



Extremely high pharmacokinetic variability



Differences in bioavailability between
different pharmaceutical products on the
market



High risk of interactions cytochrome P450
3A4 and 3A5 dependent with direct and
immediate consequences (over/under dosing)



Nephrotoxicity that is dose dependent

The drug exhibits very poor solubility in water, and,
as a consequence, suspension and emulsion forms of
the drug have been developed for oral administration
and for injection. Cyclosporine formulations are not
bioequivalent and cannot be used interchangeably.
Formulations are described as modified (Neoral)
and non-modified forms (Sandimune). Peak
concentrations are reached in two - six hours
after oral administration with non-modified
formulations and 1 to 2 hours after the modified
forms. Elimination of cyclosporine is biphasic and
is primarily biliary. Terminal half-life is variable
with formulation and patient, ranging from five to 18
hours for the modified forms and from 10 to 27 hours
for the non-modified forms.

Patients treated with the cyclosporine are at
high risk of developing renal injury. Calcineurin
inhibitor nephrotoxicity is manifested either as
acute azotemia, which is largely reversible after
reducing the dose, or as chronic progressive
renal disease, which is usually irreversible. Other
renal effects of cyclosporine include tubular
dysfunction and, rarely, a hemolytic uremic
syndrome that can lead to acute graft loss.
Metabolic abnormalities resulting from alterations
in tubular function noted with cyclosporine therapy
include hyperkalemia, hyperuricemia, metabolic
acidosis, hypophosphatemia, hypomagnesemia, and
hypercalciuria. Acute cyclosporine nephrotoxicity is
usually reversible with cessation of therapy as both
the plasma creatinine concentration and systemic
blood pressure fall toward baseline values for
that patient . The important clinical problem is to
differentiate cyclosporine-induced renal dysfunction
from acute rejection. The only definitive diagnostic
test is biopsy of the renal allograft.
Monitoring should take into account the blood
level of cyclosporine and the therapeutic interval
(different for renal, liver and heart transplantation)
and the correlation that exists between this
interval and acute graft rejection, on one hand,
and nephrotoxicity, on the other hand.With eighty
percent of cyclosporine sequestered in erythrocytes,
whole blood is the preferred specimen for analysis.
Peak concentrations (C2) are defined as samples
collected two hours post-dose. High levels of
cyclosporine in peak samples are correlated with
reduced rejection rates, especially in the first year
after transplant surgery.Therapeutic ranges usually
are based on specimens drawn at trough or C0
(i.e. immediately before the next scheduled dose).
Recommended therapeutic ranges for cyclosporine
for various transplants are described in Table 1 and
Table 2.

Table 1. Recommended Therapeutic ranges for Cyclosporine (C0 levels)

Cyclosporine Levels

Post Renal Transplant
Up to 2 months

200-300 ng/ml

3 months

200 ng/ml

4 - 12 months

80-180 ng/ml

Cyclosporine Levels

Post Liver Transplant
Less than or equal to 1 month

350-450 ng/ml

2-6 months

250-350 ng/ml

More than 6 months

170-240 ng/ml

17
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Post Cardiac Transplant

Cyclosporine Levels

Less than 6 weeks

300-420 ng/ml

6-12 weeks

180-300 ng/ml

More than 12 weeks

120-180 ng/ml

Table 2. Recommended Therapeutic ranges for Cyclosporine (C2 levels)

Cyclosporine Levels

Post Renal Transplant
Up to 1 month

1700 ng/ml *

2 months

1500 ng/ml *

3-4 months

1200 ng/ml *

5-6 months

1000 ng/ml *

7-12 months

800 ng/ml *

* (+/- 20%)

The purpose of monitoring is to prevent rejection
(graft survival) and improved tolerance (avoidance
of adverse reactions, particularly nephrotoxicity
and too high immuno-suppression). Trough (C0)
residual concentration is directly correlated with
nephrotoxicity, but it is not a useful marker for

prediction of acute rejection. Both nephrotoxicity
and acute rejection are better correlated with the
area under the concentration-time curve measured
between 0 - 4 hour or 0 -12 hour (AUC0-4, AUC012). These values can be better estimated using the
value of C2 than the residual concentration (C0).

Tacrolimus for Prevention of Transplant Rejection
Dr Shabnam Dildar
Chemical Pathology

Tacrolimus (previously known as FK506) is
a 23-membered macrolide lactone antibiotic
isolated from the fermentation broth of a
fungus Streptomyces tsukubaensis. It is an
immunosuppressive agent belonging to the
calcineurin inhibitor group. It emerged as a
valuable therapeutic alternative to
cyclosporine following solid organ
transplantation, was granted approval by the
U.S. Food and Drug Administration (FDA) for
preventing rejection after liver (1994), kidney
(1997), and heart transplants (2006). It is also
used for the therapy of autoimmune diseases
and to reduce inflammation in inflammatory
bowel disease, severe steroid-refractory or
steroid-dependent ulcerative colitis, and
Crohn’s disease.
18

Mechanism of Action
After entry into the cell, tacrolimus binds to
the FK-binding protein (FKBP) which is an
intracellular cytoplasmic immunophilin. The
drug-immunophilin complex binds and inhibits
the activity of the phosphatase activity of
calcineurin. The calcium/calmodulin-dependent
protein phosphatase interrupts the calciumdependent signal transduction pathway in
T-cells. Inhibition of calcineurin by tacrolimus
leads to interference with translocation to the
nucleus of various nuclear factors involved
in the transcription of cytokine genes, such
as the cytosolic subunit of the nuclear factor
of activated T-cells. Thus preventing its
entrance into the nucleus. Therefore leads to
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the inhibition of T-cell activation, resulting in
immunosuppression. Although this activity is
similar to that of cyclosporin, studies have shown
that the incidence of acute rejection is reduced by
tacrolimus use over cyclosporin. Although shortterm immunosuppression concerning patient and
graft survival is found to be similar between the
two drugs, tacrolimus results in a more favorable
lipid profile, and this may have important longterm implications given the prognostic influence
of rejection on graft survival.
Tacrolimus Metabolism
Tacrolimus is highly lipophilic and is excreted
from the body after receiving extensive
metabolism. Tacrolimus is metabolized by
Cytochrome P450 3A4 (CYP3A4), thus its
concentrations are affected by drugs that inhibit
(calcium channel blockers, antifungal agents,
some antibiotics, grapefruit juice) or induce
(anticonvulsants, rifampin) this enzyme. Target
steady-state concentrations vary depending
on clinical protocol, the presence or risk of
rejection, time from transplant, type of allograft,
concomitant immunosuppression, and side effects
(mainly nephrotoxicity). Optimal trough blood
concentrations are generally between 5.0 and
20.0 ng/mL. Adverse reactions tend to occur
the most frequently in the first few months after
transplantation and decrease with time possibly in
line with reductions in its concentration. Adverse
reactions include nephrotoxicity, neurotoxicity,
diabetogenesis, gastrointestinal disturbances,
hypertension, infections and malignant
complications.
Therapeutic Drug Monitoring of Tacrolimus
Tacrolimus has a low therapeutic index with a high
inter-and intra-pharmacokinetic variability, and
possesses several side effects and drug interactions.
All these factors requires individualized monitoring
of the drug levels in blood. Therapeutic monitoring
of tacrolimus is useful for guiding dosage
adjustments to achieve optimal immunosuppression
while minimizing dose-dependent toxicity.
Therapeutic drug monitoring of tacrolimus is usually
initiated on the second or third day of therapy. It is
continued for the first two weeks, three - seven times
per week; with a gradual reduction in the monitoring
frequency. Therapeutic Drug Monitoring of
tacrolimus is important for monitoring whole blood
tacrolimus concentration during therapy, particularly
in individuals who are on CYP3A4 substrates,

inhibitors, or inducers. Is also essential to monitor
tacrolimus levels when adjusting dose to optimize
immunosuppression while minimizing toxicity and
also for evaluating patient compliance.
Some key points to note while monitoring tacrolimus
are:
Peak

tacrolimus levels in whole blood are
achieved about one - two hours following oral
administration

The

cornerstone of tacrolimus evaluation is the
trough level obtained 12 hours after the
administration of the drug. This measurement
provides a good indication of the total drug
exposure.

There

is not a good correlation, as with some
other medications, between the dose of tacrolimus
given and level of drug in the blood

Absorption

and metabolism of oral doses of
tacrolimus can vary greatly between people and
even in the same person depending on the time of
the dose and what, if any, food has been eaten

Tacrolimus

can cause kidney damage
(nephrotoxicity), especially in high doses.
Measuring levels in patients who have had a
kidney transplant may help to distinguish between
kidney damage due to rejection (because drug
level is low) and kidney damage due to tacrolimus
toxicity (drug level is high)

Specimen Type and Therapeutic Range
Since 90 per cent of tacrolimus is in the cellular
components of blood, especially erythrocytes, whole
blood is the preferred specimen for analysis of
trough concentrations.
Target range for trough whole-blood sample is
5-20 ng/ml. The recommended therapeutic range
applies to trough specimens drawn just before the
next dose (i.e. immediately before a scheduled
dose). Blood drawn at other times will yield higher
results. Higher levels are often sought immediately
after transplant, but as organ function stabilizes at
about 4 weeks from transplant, doses are generally
reduced in stable patients for most solid organ
transplants. Trough concentrations should be
maintained below 20 ng/mL. Preferred therapeutic
ranges may vary by transplant type, protocol, and
co-medications.
19
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An Approach to Diagnosis of Infections in
Febrile Neutropenic Patients
Dr Faryal Saleem
Microbiology

Febrile neutropenia is defined as ‘single oral
temperature of 38.5°C or more or a temperature
of 38°C recorded on three different occasions
within a 24 hour period at least four hours apart
in a neutropenic patient’. Here, neutropenia
maybe defined as an absolute neutrophil count
(polymorphnuclear cells) of 500/ml or less.
In as many as 50 per cent of the cases, infections are
the main cause of febrile neutropenia. The infections
maybe bacterial, fungal or viral in origin but many a
times typical signs and symptoms of these infections
are absent due to the altered host immune responses.
Fever might be the only manifestation thus it is
important for physicians to do stringent monitoring
of patients especially when they are undergoing a
neutropenic phase during their chemotherapy.
It is imperative that all measures are taken to
diagnose and treat any infections that may be a

cause of febrile neutropenia in patients. Antibiotic
therapy must be started within one hour of the patient
reaching the hospital. Apart from complete blood
count, including differential leukocyte counts and
other biochemical markers of infections, there are
various tests that are used in a laboratory to diagnose
infections, with blood cultures being the primary
diagnostic modality. For blood cultures to yield
valuable results it is important that they are taken
with standard protocol of aseptic techniques. At
least two sets of blood cultures from two separate
venipuncture sites are recommended. If indicated,
cultures from any other clinically suspicious site may
also be taken. Table 1 shows common organisms
which are isolated from different clinical specimens
through routine culture and molecular methods.
Positive blood cultures are gram stained and
preliminary information is conveyed to the clinician
so that any modification in empirical therapy

Table 1. Common Organisms isolated in various specimen cultures of Febrile Neutropenia

Causative Agent
Bacteria

Organisms
Staphylococcus aureus

Specimens

Diagnostic Modalities

Blood, pus, body fluids, swabs from
wounds etc.

Culture and sensitivities

Blood, urine, pus, body fluids,
swabs from wounds etc.

Culture and sensitivities

Mycobacterium species

Sputum, bronchoalveolar lavage
fluid, pus etc.

Culture and sensitivities

Candida species

Blood, urine, body fluids, tissue
culture etc.

Gram staining, culture and
sensitivities, PCR

Tissue culture, skin scrapings, etc.

Gram staining, fungal smear and
culture and sensitivities,
PCR

Streptococci
Pseudomonas species
Enterococci
Escherichia coli
Klebsiella species

Fungi

Mucormycosis

Viral

Aspergillus spp

Tissue culture, skin scrapings, etc.

Cytomegalovirus

Bronchoalveolar lavage fluid,
vesicular/pustular fluid etc.

Herpes simplex virus
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fungal smear and culture and
sensitivities, PCR
PCR
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may be instituted. Several rapid diagnostics and
susceptibility methods have been developed from
positive blood culture vials. Direct disc diffusion
from positive vials is currently in use in several
laboratories including ours. Molecular identification
using multiplex PCR, matrix assisted laser desorption
ionization- time of flight (MALDI-TOF), fluorescent
in-situ hybridization (FISH) are just a few examples
of advancements in rapid identification techniques
which are expected to improve patient management.
Similarly susceptibility testing methods employing
detection of resistance associated gene mutations

can provide additional benefit in guiding empirical
therapy.
Thus, it is essential for the clinicians to evaluate the
patients suffering from febrile neutropenia carefully
and send all the relevant investigations without any
delay to find out the etiology of fever as quickly as
possible. In most of the cases a positive blood culture
with proper identification and susceptibility profile of the
causative agent is enough to warrant an early diagnosis
of infection. In these cases, timely use of appropriate
antimicrobials may prove to be lifesaving for the patient.

Significance of CMV Antigenemia Assay In
Renal Transplant Patients
Waqas Khan and Saher Faisal
Molecular Pathology

Introduction
Pp65 CMV antigenemia test allows the indirect
immunofluorescence detection of internal matrix
phosphoprotein (protein kinase) 65-68 KD (pp65)
of Human Cytomegalovirus (HCMV) in peripheral
blood leukocytes. The pp65 detection in peripheral
blood leukocytes allows the diagnosis of acute or
reactivated infection. The HCMV pp65 antigenemia
is a rapid, quantitative, simple, sensitive easy for
the diagnostic of active Cytomegalovirus infection.
Antigenemia is more sensitive than viral isolation
and rapid culture serology. In all cases, the sensitivity
is 100% in symptomatic patients. Antigenemia can
be detected from several days to one week before the
onset of symptoms. Antigenemia is successfully used
in the diagnostic and follow-up of HCMV infections
in heart, heart-lung liver, kidney, and bone-marrow
graft recipients and in AIDS patients.

light allowing visualization of the complex by
fluorescence microscopy. Nuclear fluorescence
indicates a positive specimen. Uninfected cells
counter-stain dull red due to the presence of Evans
blue in the FITC conjugated antibody reagent.
Utility of the Assay
HCMV antigenemia test is recommended for
the diagnosis of patients infected with CMV
virus as this test is used to detect the antigen of
cytomegalovirus (CMV). This test may also be used
when a CMV infection is suspected in patients with
HIV or organ transplant recipients.
Results Interpretation
The HCMV isolation from leukocytes of peripheral
blood (viremia) and/or pp65 antigenemia are

Principle of the Assay
This method uses a monoclonal antibodies pool
which recognizes two epitopes of the protein (pp65)
expressed in the nucleus of peripheral blood HCMV
infected polymorph nuclear and mononuclear
cells, during blood dissemination. Fluorescein
isothiocyanate (FITC) conjugated antibody will bind
to the antigen-antibody complex. Unbound conjugate
is removed by washing with PBS. FITC exhibits an
apple green fluorescence when excited by ultraviolet

Figure 1. Antigenemia Signal from a CMV Positive Patient
Source: virology-online.com/viruses/CMV4.htm

21

VOL. 40, ISSUE 2

NOVEMBER 2014

evidence for active systemic infection. A single
stained cell indicates a positive antigenemia.
Conclusion
Antigenemia is more sensitive than viral isolation,
rapid culture and serology. Antigenemia can be

detected from several days to one week before the
onset of symptoms, and from two to 25 days before
rapid culture. Antigenemia is also positive for a
longer period than viremia demonstrated by co-culture.
This test can be even performed by laboratories where
the culture are not available, and only requires as
specific apparatus a simple cytocentrifuge.

Pretransplant Serological Evaluation
Dr Hafsa Majid
Chemical Pathology

The success of solid organ transplantation requires
careful selection of transplant recipient through a
process of medical evaluation and screening. Two
major complications occurring due to long term
immunosuppression after transplant are infections
and malignancy. That is why screening a potential
transplant recipient for infectious diseases is an
important pre-transplant component. Such screening
may lead to the discovery and treatment of occult
active infection improving patient outcomes,
may help determine post-transplant prophylactic
strategies, or may disqualify the recipient from
receiving a transplant.

transplantation . The United Network for Organ
Sharing (USA) has issued this list of required
infectious disease screening tests for both organ
donors and potential recipients. Once a patient has
cleared the initial evaluation, they may be listed for
solid organ transplant.

Recommended hepatitis B (HBV) screening tests
include hepatitis B surface antigen (HBsAg) and
antibody (HBsAb) and hepatitis B core antibody
(HBcAb). HBsAg positive or patients with any
evidence of prior hepatitis B infection (HBsAg
negative and HBcAb positive) can be further
assessed by HBV DNA and treated if appropriate.
Even patients with no evidence of viremia and
At the time a patient is identified as a potential
isolated HBcAb positivity may experience HBV
transplant recipient, an initial evaluation including
reactivation post-transplant occasionally leading to
a detailed history and physical examination is
fulminant hepatitis. Patients with isolated HBsAb
required to assess the candidate’s suitability for
and a history of prior vaccination have demonstrated
transplantation. This assessment includes laboratory
immunity to infection with hepatitis B and do not
screening tests and serological evaluation (Table
require HBV immunization pre-transplant. Screening
1) to establish the candidate’s prior exposure to
for the presence of antibody to hepatitis C virus
common organisms that may reactivate after organ
(HCV) in all candidates
Table 1. Pre-Transplant Serology Recommended for All Potential Organ Recipients and Donors
is necessary and further
Pre-Transplant Serology Includes
testing with HBV RNA if
positive. Transplantation
Hepatitis B serology (HBsAg, HBcAb, HBsAb)
of non-hepatic organs
Hepatitis C Ab
into an HCV seropositive
recipient may result in
HIV serology
accelerated hepatitis and
CMV serology (IgM and IgG)
liver failure. Screening
for viral pathogens such
EBV serology
as HIV is a required part
Toxoplasma IgG
of the pre-transplant
evaluation. Though not an
Interferon gamma release assay or PPD skin test for Mycobacterium tuberculosis
absolute contraindication
Rapid plasma reagin (RPR) or specific treponemal testing
to transplant, HIV
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infection must be documented and viral replication
controlled prior to surgery.
Screening for cytomegalovirus (CMV), a common
post-transplant infection is also recommended as it
is potentially transmissible through transplantation
and carry a predictable disease risk. The seronegative
recipient for CMV Ab receiving a seropositive
donor’s organ has the greatest risk of disease.
Post-transplant cytomegalovirus may occur in any
recipient positive (R+) case as well as in recipient
negative patients exposed to the virus through
blood transfusion or other close contact. EpsteinBarr virus (EBV) infection is a risk factor for posttransplant lymphoproliferative disease, particularly
in seronegative patients who develop primary EBV
infection due to seropositive donor. Screening for
EBV can be done by testing Epstein Barr Nuclear
Antigen (EBNA) IgG, EBV-Viral Capsid Antigen
(VCA) IgM and EBV-VCA IgG. Primary infection
is indicated by positive EBV-VCA IgM, EBV-VCA
IgG and negative EBNA IgG. While past infection is
presence of positive EBNA IgG, EBV-VCA-IgG and
negative EBV-VCA IgM.
Although antibiotics given pretransplant provide
coverage for infection with Toxoplasma, but
screening for exposure to the parasite, Toxoplasma
gondii is routinely performed. Because the organism
can form cysts in organs especially myocardial
tissue, so seronegative recipients of seropositive
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heart donors are at greatest risk for reactivation posttransplant. Reactivation disease in other seronegative
organ transplant recipients can result in a nonspecific
syndrome of multiorgan failure post-transplant that is
often fatal if not recognized.
Latent bacterial infection with syphilis can be
assessed using Rapid plasma reagin testing.
Positive tests can be further confirmed with
specific treponemal assays and treated. While
latent infection with Mycobacterium tuberculosis
can be detected using Purified protein derivative
skin testing or interferon-gamma release assays for
Mycobacterium tuberculosis. False negative results
may occur in patients with organ failure as little is
known about the efficacy of such testing in patients
who may be immunocompromised as a result of
pre-transplant organ dysfunction. Patients who test
positive for latent tuberculosis should be evaluated
clinically and radiologically for active disease
and can be treated for latent tuberculosis where
indicated.
Further to these tests all transplant candidates should
also be tested for active infection with bacterial
pathogens as clinically indicated. Active infections
should be fully treated prior to transplant whenever
possible. A thorough assessment of potential
recipients prior to organ implantation will improve
graft and patient survival, lower costs, and reduce
infectious complications post-transplant.

Significance of Panel Reactive Antibody
Testing in Renal Transplant Patients
Maheen Hassan, Sheeba Parveen, Abdul Jabbar and
Tariq Moatter
Molecular Pathology

Introduction
The immune system makes abundance of proteins
called antibodies. When an antibody recognizes the
foreign proteins in case of infectious agent, organ
transplant, blood transfusion and/or as a result of
pregnancy, it recruits other proteins and cells to fight
these foreign bodies off.
In case of an organ transplant patient, when one of
the organs of the patient has failed to work due to

illness or injury, antibody screening is essential.
Before organ transplant, doctors must match if the
recipient has pre-existing panel of antibodies that
may react against donor’s organ in order to reduce
the chances of graft rejection.
Panel Reactive Antibody (PRA) is an immunological
test routinely performed on the blood of people
awaiting organ transplantation. The PRA score
is expressed as a percentage between 0 per cent
and 99 per cent that represents the likelihood of
23

VOL. 40, ISSUE 2

NOVEMBER 2014

the recipient’s blood having an antibody against a
particular donor. It represents the proportion of the
population to which the person being tested will
react via pre-existing antibodies. These antibodies
target the Human Leukocyte Antigen (HLA), a
protein found on most cells of the body.
A high PRA usually means that the individual is
primed to react immunologically against a large
proportion of the population. Individuals with a
high PRA are often termed “sensitized”, which
indicates that they have been exposed to “foreign”
(or “non-self”) proteins in the past and have
developed antibodies to them. Transplanting organs
into recipients who are “sensitized” to the organs
significantly increases the risk of rejection, resulting
in higher immunosuppressant requirement and
shorter transplant survival. People with high PRA
therefore spend longer waiting for an organ to which
they have no pre-existing antibodies.
Anti HLA antibodies are usually referred to as panel
reactive antibodies (PRA) test that sometimes as
referred to as percent reactive antibody, since the
result is expressed as percentage.
Utility of the Assay
PRA is a very useful marker in renal transplantation.
Monitoring panel reactive antibody levels is
important with kidney transplant candidates. High
PRA levels mean that doctors have more difficulty
locating a matching donor, which can present a
problem if an immediate transplant is necessary.
This means that patients with a higher PRA count
may have to wait much longer for a matching donor
kidney. Patients with elevated PRA levels are also
more likely to experience organ rejection and must

be given a more advanced regimen of anti-rejection
medications.
Principle of the Assay
Panel Reactive antibody testing utilizes a panel of
color-coded beads, which are coated with purified
HLA antigens. Test serum is first incubated with
beads, any HLA antibodies present in the test serum
bind to the antigens and then are labeled with
R-Phycoerythrin (PE)-conjugated Goat anti-human
IgG. The flow analyzer detects the fluorescent
emission of PE from each bead, allowing almost
real-time data acquisition.

Detection by R-Phycoerythrin Conjugated Antibody

1

Add sample.

2

Wash.

3

4
Add R-PE
Wash.
conjugated Anti-IgG.

5

Read.

Figure 1. Principle of Panel reactive Antibody Testing
Source: www.szabo-scandic.com/uploads/media/OLI_ProductCatalog2013-14_web.pdf

Conclusion
Till date, PRA is the sole established quantitative
indicator of pre-transplantation immunologic
responsiveness. The exact incidence of humoral
alloimmune responses after kidney transplantation
is still uncertain, as routinely post-transplantation
monitoring of antibodies is not performed. An
allograft is the most important cause for development
of antibodies, but transfusions, infections, and
pregnancy can also stimulate antibody formation; the
degree of sensitization is stronger and more prolonged
when different causes act together in the same person.

Importance of Monitoring Cytomegalovirus
(CMV) and BKV (Polyomavirus) Infection in
Renal Transplant Patients
Dr Mahesh Kumar
Molecular Pathology

Kidney transplantation is indicated in patients
with end stage renal disease, patients who have
estimated renal function <20 per cent of normal on
24

two sequential determinant or dialysis dependent
or significant signs and symptoms of uremia such as
nausea, loss of appetite, insomnia or chronic fatigue
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or acid-base or electrolyte irregularities unresponsive
to oral treatment. Viral infections i.e. CMV and BKV
are major problem in these allograft recipients, most
commonly one - six months after transplantation,
results from reactivation of “latent” viral infection
in the host or from the graft. Therefore, monitoring
for reactivation of these viral infections should be
routine.
Viral Latency and Reactivation
The nature of viral latency varies with the specific
virus, the tissue infected, and the nature of the
host immune response. Some latent viruses
are metabolically inactive, whereas others are
constantly replicating at low levels determined by
the effectiveness of the host’s immune response.
Multiple factors contribute to viral activation after
transplantation, including immune suppression
(especially reduction of cytotoxic immunity), graft
rejection and therapy, inflammation (cytokines),
and tissue injury. Cellular pathways activated after
transplantation are involved in the control of viral
replication, including nuclear factor KB, IKB, and
JAK-STAT (the Janus family of protein tyrosine
kinases [JAKS] and signal transducers and activators
of transcription [STAT]proteins) . Treatment of
rejection can also result in a significant release of
proinflammatory cytokines, including TNF-alpha
and IL-1B, which may increase viral replication.
Viral latency may be interrupted periodically,
leading to reactivation and spread of infectious virus
with recurrent disease. For CMV, viral genomes
can be found in CD14+ monocytes and CD34+
progenitor cells, but the primary reservoir for latent
cytomegalovirus and the mechanisms by which
latent CMV infection is maintained are unknown.
Subclinical activation of CMV is common. CMV
reactivation has been extensively studied. Allogeneic
immune responses and fever (via TNF alpha) have
been shown in vitro to up-regulate both CMV
promoter activity and viral replication. Immune
suppression is not essential for the reactivation
of latent CMV but serves to perpetuate such
infections once activated. For other viruses (e.g.
BK polyomavirus), specific types of tissue damage
(warm ischemia, reperfusion injury, but not cold
ischemia) may precipitate viral activation. Warm
ischemia and reperfusion have been linked to an
inflammatory state in grafts (via activation of TNFalpha, nuclear factorKB, neutrophil infiltration,
and nitric oxide synthesis), tubular-cell injury, and
enhanced expression of cell-surface molecules.
These changes contribute to viral activation.
Thus, immune injury, inflammatory cytokines,

and ischemia-reperfusion injury stimulate viral
replication and alterations in the expression of virus
specific cell-surface receptors. The host response
is also less effective because of the mismatch in
major histocompatibility antigens between the organ
donor and host, which reduces the efficacy of direct
pathway antiviral cellular immune responses. These
factors render the allograft susceptible to invasive
viral infection.
Clinical Value of Viral Load Screening and
Monitoring
CMV
Cytomegalovirus is the “classic” transplant
associated viral infection. It causes fever, malaise,
leucopenia, thrombocytopenia, and allograft
dysfunction. Even asymptomatic infection with
CMV is associated with renal allograft dysfunction,
mortality, and graft loss, despite early detection and
treatment of asymptomatic infections. Poor outcomes
are associated with poor HLA matching and may
reflect increased immunogenicity, inflammatory
response, or failure to clear CMV. Figure 1 showing
CMV virion structure.

pp65
pUL47
pUL48
pp150
pp28
pp71

Figure 1. The HCMV virion.
The cartoon represents (not to scale) an average HCMV infectious viral
particle. Abundant tegument proteins are listed. The large shapes on
the surface of the virion represent various virally encoded membrane
glycoproteins.
Source: mmbr.asm.org/content/72/2/249/F1.large.jpg

BKV
The BK virus, named after the initials of the patient
in which it was first isolated is the most recently
recognized viral pathogen affecting renal transplant
recipients. It was originally reported in 1971. Primary
infection usually occurs early in the childhood, at a
median age of five years, and is characterized by low
upper respiratory tract morbidity or is asymptomatic.
Following primary infection, BKV remain latent in
25
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different sites, including the Reno urinary tract, as the
epidemiologically most relevant latency site, B cells,
brain, spleen, and probably other organs. Periodical
reactivation may occur in both immunocompetent
individuals (in 0 per cent up to 62 per cent) and
immunocompromised patients and is evidenced
by asymptomatic viruria. In the current era of
immunosuppression, BK virus causes nephropathy
in up to eight per cent of recipients, and frequently
results in allograft loss or permanent dysfunction. It
presents as an asymptomatic gradual rise in creatinine
with a tubulointerstitial nephritis that mimics rejection
on biopsy and produces a treatment dilemma. Viral
replication begins early after transplantation and
progresses through detectable stages - viruria, then
viremia, then nephropathy. Figure 2 showing BK virus
genome structure.

Qualitative CMV PCR
Principle: DNA is extracted from blood followed by
PCR amplification of conserve region of the DNA
polymerase of CMV by real time PCR. Human
apoprotein gene is also amplified simultaneously and
serves as internal control. Interpretation of the assay
is based on the strength of fluorescence signals.
Quantitative CMV PCR
Principle: DNA extraction from plasma is followed
by PCR amplification performed in real time PCR
instrument. The PCR primers and probes target genes
within the CMV genome and provide viral load in
IU/ml. Lower detection limit of the assay is 30 IU/
ml. PCR results are shown in Figure 3.
A1
A2
F4
F5
H6
H9

Active Infection
Latent Infection
Negative CTRL
Threshold
Cycle Ct

A1
A2
F4
F5
H6
H9

32.5
33.1
40.2
40.2
N/A
N/A

Figure 3. Two positive (active infection and latent infection) clinical
samples was tested . All positive samples were amplified and the cycle
threshold show the difference between an active infection and a latent
infection

Quantitative BKV
Figure 2. Schematic representation of the gene organization in the BK
virus (BKV) genome. The double circle represents the double stranded
DNA genomes. The genome is divided into three regions. The early
region encodes three regulatory proteins (Agt, AgT, T’). The late region
specifies four structural proteins and agnoprotein (VP1, VP2, VP3,
VPx). The non-coding control region contains the elements for the
control of viral DNA replication ( ori) and viral gene expression The
arrows indicate the positive and negative strands according to the
direction of viral transcription
Source: Mischitelli et al. Virology Journal 2008 5:38

Principle: DNA is extracted from serum or urine
sample followed by amplification by real time PCR.
The PCR primers and probes target genes within the
BKV genome and provide viral load in IU/ml. PCR
results are shown in Figure 4.

Diagnosis
Molecular techniques including PCR are monitoring
tests of choice. Qualitative CMV PCR detects only
presence/absence of viral DNA and is useful in
systemic CMV infection in immunocompromised
patients, antenatal diagnosis of congenital CMV
infection, CMV retinitis and encephalomyelitis
whereas quantitative CMV detects “viral load”
which identifies both virologic response (guiding
therapy duration) as well as possible presence of
antiviral resistance. Molecular Pathology department
Aga Khan hospital is performing qualitative and
quantitative CMV and quantitative BK virus PCR.
26

Figure 4. Result interpretation: Quantification Standards (black), a
positive (red) and a negative sample (blue) displayed in the Amplification
Plot (A) and Standard Curve analysis (B).

Conclusion
Both viruses are opportunists in the setting of
transplantation, with potential effects, the clinical
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problems currently associated with either virus
are fundamentally different. CMV can affect
any organ system, with substantial morbidity
and mortality, all of which can be essentially
controlled by effective antivirals. BKV on
the other hand causes severe pathologies in
the Reno urinary tract in a limited number of
kidney transplant recipients. Access to invasive
procedures and biopsy workup is required for
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definitive diagnosis of CMV and BKV disease.
However, for both agents, the most relevant
diagnostic study in the clinical setting is early
detection and quantification of virus replication
in blood. Assays quantifying virus-specific
cellular immune responses in real-time are
important new avenues to be explored to better
predict risk of replication and disease and to
optimize clinical management.

Meeting Report: Committee on Reference
Intervals and Decision Limits (C-RIDL),
IFCC Meeting, Symposium and Workshop
Dr Lena Jafri
Chemical Pathology

The Committee on Reference Intervals and
Decision Limits (C-RIDL), IFCC Meeting related
to ‘Global Multicenter Study on Reference Values’
was held at the Fukuoka International Convention
Center, Japan on 24th and 25th November 2014.
It was chaired by Professor Kiyoshi Ichihara,
Professor Department of Clinical Laboratory
Science, Yamaguchi University Graduate School
of Medicine, Chair, C-RIDL, IFCC and the
coordinator of the Global Multicenter Study on
Reference Values. After a welcome to participants
and a short tour-de-table, Prof. Ichihara described
background and objectives of the meeting. He
updated the group that there were nineteen
countries from 5 continents collaborating in
this global study; collaborating countries were
Turkey, Japan, China, India, Philippines, US, UK,
Argentina, Saudi Arabia, Kenya , Nigeria, Russia,
Nepal, Bangladesh, Pakistan, Denmark, Egypt and
Malaysia. He displayed the current status of each
country, the number of analytes proposed, country
codes, sample size, test panels and financial support
of each region.
It was well attended by, principal investigators
and co-investigators of the global C-RIDL study
from various countries; India, Saudi Arabia, China,
Russia, Nepal, South Africa, Philippines, Pakistan.
Bangladesh, Egypt and Malaysia. The meeting
continued as each country representative gave a
quick update and progress report of their study.
Representatives invited from Pakistan were Dr

Lena Jafri, from Section of Chemical Pathology,
Department of Pathology & Microbiology AKUH
and Prof. Dr Brig. Dilshad, from Armed Forces
Institute Rawalpindi. The Aga Khan University
is one of the collaborators of this study and there
is an additional interest in exploring influence of
ethnicity on reference intervals within Pakistan.
This is a unique opportunity for AKUH since no
reference interval is available which has been
derived from the local population. AKUH with its
countrywide extensive network is well equipped to
take on a study of this magnitude.
Prof. Ichihara explained to the members the
difference between primary and secondary
exclusion criteria. He clarified to the members
that to reveal a comprehensive picture of
reference intervals, C-RIDL is coordinating this
multicenter RI study with recruitment of a sufficient
number of individuals to ensure traceability and
harmonization of the test results. This was followed
by suggestions and tips for recording questionnaire
and use of codes for drugs while entering data
was advised. The morning meeting was followed
by a Symposium “IFCC Global multicenter study
on reference values: major findings and their
implications” in the afternoon. It was coordinated
by Prof. Ichihara and Prof. Rajiv Erasmus from
Stellenbosch University, South Africa. This session
had several speakers who discussed findings from
their respective population. The study collaborators
from China, Saudi Arabia, India and South Africa
presented their results of their regions using the
same IFCC-CRIDL protocol. This was followed by
an intense question answer session.
27
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Investigators and co-investigators from various regions of the world at the ‘Committee on Reference Intervals and Decision Limits
(C-RIDL), IFCC’ Meeting

On the 25th Nov C-RIDL meeting continued and all
the members gathered at the Fukuoka International
Convention Center again. Extensive discussion on
statistical tools used like parametric versus nonparametric, bootstrap method for smoothing the
reference intervals and prediction of 90% confidence
interval of reference intervals limits was done. This
meeting was followed by a workshop “Hands-on:
Statistical methods for the reference interval study”.
The new and latest software ‘RI-Master’ made by
Reo Kawano and Prof. Ichihara was introduced
to the group. The software was provided to all the
participants and a hands-on training session was
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given. This session enabled the participants to get to
know the statistical software, removing curiosity and
perhaps some trepidation.
Early morning on the 26th November the group
set off for an excursion to Kumamoto where the
witnessed volcanic unrest of Mount ‘Aso’, hot
springs and the four hundred year old Kumamoto
Castle. This trip provided us an opportunity to
interact and share ideas in an informal setting. The
event ended with a traditional multi-course Japanese
style farewell dinner, Kaiseki (
) in a quiet
tranquil environment.
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Details Of Therapeutic Drug Monitoring
Hafsa Majid, Chemical Pathology
S. No

Drug

Time of Sample Collection

Therapeutic Ranges

Reporting

1.

Valproic
Acid

Trough (predose)

50 - 100 μg/ml

Same day

2.

Tegretol

Trough (predose)

4-12 μg/ml

Same day

3.

Phenytoin

Trough (predose)

10-20ug/ml

Performed from
Monday to Friday and
reported same day

4.

Phenobarbital

Trough (predose)

10-40ug/ml

Performed from
Monday to Friday and
reported same day

5.

6.

Gentamicin

Vancomycin

Peak testing (after 2-4 hours post
dose) Trough (predose)

Trough Vancomycin concentrations
are the most accurate and
practical method to guide
Vancomycin dosing. Serum trough
concentrations should be obtained
prior to the fourth or fifth dose.

Peak:
Less severe infection 5-8 ug/ml
Severe infection 8-10 ug/ml
Trough:
Less severe infection<1.0ug/ml
Moderate infection<2.0ug/ml
Severe infection<4.0ug/ml
Toxic:
Trough > 2.0 ug/ml
Peak > 10.0 ug/ml

Therapeutic concentration >10 ug/ml
Trough 15-20 ug/ml

Same day

Same day

Trough 5-10 ug/ml
Peak 20-25 ug/ml
7.

Amikacin

Peak testing (after 2-4 hours post
dose) Trough (predose)

Toxic:
Trough > 10 ug/ml
Peak > 35 ug/ml

Same day
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S. No

8.

9

Drug

Cyclosporin

Cyclosporin
C2
Monitoring

Time of Sample Collection

Trough (predose)

Peak testing (after 2-4 hours post
dose)

Therapeutic Ranges

Reporting

Post renal transplants:
Upto 2 months 200-300 ng/ml
3 months 200 ng/ml
4-12 months 80-180 ng/ml
Post liver transplants:
≤ 1 month 350-450 ng/ml
2-6 months 250-350 ng/ml
>6 months 170-240 ng/ml
Post cardiac transplants:
<6 weeks 300-420 ng/ml
6-12 weeks 180-300 ng/ml
>12 weeks 120-180 ng/ml

Performed from
Monday to Saturday
and reported same day
Results of inpatients
undergoing transplant
are reported within 4
hours after receiving
specimen.

Post renal transplant:
Upto 1 month 1700 ng/ml
2 months 1500 ng/ml
3-4 months 1200 ng/ml
5-6 months 1000 ng/ml
7-12 months 800 ng/ml

Performed from
Monday to Saturday
and reported same day
Results of inpatients
undergoing transplant
are reported within 4
hours after receiving
specimen.
Performed on
Wednesday and
reported next day
Results of inpatients
undergoing transplant
are reported within 4
hours after receiving
specimen.

10.

Tacrolimus

Trough (predose)

5-20 ng/ml

11.

Methotrexate

Trough (predose) Collect sample
after 72 hours of therapy

Non-toxic concentration <0.1 umol/l

Same day

12.

Lithium

Trough (Predose or after 12 hours
post dose)

Therapeutic Range: 0.6 - 1.2mmol/l
Toxic: >2.0mmol/l

Same day

13.

Theophylline

Peak testing (after 2-4 hours post
dose) Trough (predose)

Therapeutic Range 10-20ug/ml

Same day

14.

Digoxin

Peak tissue concentration (after 8
hours post dose)
Trough (predose)

Therapeutic Range 0.9-2.0ng/ml
Toxic >2.0ng/ml

Same day

Special instruction: Mention drug dosing frequency, route and sample is trough or peak. Mention STAT on the request
slip if results are needed urgently.
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Health Screening Package
Tests
CBC
Urine D/R
Stool D/R
Fasting Gulcose
Fasting Cholestrol
Serum Creatinine
Liver Function Test
Total
Discount
Package Price after discount (rounded to 10)

Extended Health Screening Package
Tests
CBC
Urine D/R
Stool D/R
Fasting Gulcose
Serum Creatinine
Liver Function Test
Lipid Profile
HepBs Ag
HepC AB

Tests

Macrocytic Package

Total
Discount
Package Price after discount (rounded to 10)

Vitamin B12
RBC Folate
Total
Discount
Package Price after discount (rounded to 10)

Bone Health Screening Package
Tests
Calcium
Albumin
Corrected Total Calcium (calculated value)
Phosphorus
Magnesium
Creatinine
PTH
ALP
25 OH VIT D
Total
Discount
Package Price after discount (rounded to 10)

Price
700
380
390
370
600
660
1,450
4,550
910
3,640

Price
700
380
390
370
660
1,450
2,250
1,300
2,400
9,900
1,980
7,920

Price
2,000
1,990
3,990
790
3,200

Price
600
400
60
620
1,040
660
2,650
500
3,500
10,030
2,000
8,030

410
410
410
410
600
660
380
60
3,340
660
2,680

Price

THE AGA KHAN UNIVERSITY HOSPITAL,
CLINICAL LABORATORIES - KARACHI
Renal Function Test Package
Tests
Serum Sodium
Serum Chloride
Serum Potassium
Serum Bicarbonate
Blood Urea Nitrogen
Serum Creatinine
Urine D/R
Anion Gap (calculated value)
Total
Discount
Package Price after discount (rounded to 10)

600
400
60
620
3,500
2,650
500
6,100
14,430
2,880
11,550

Price

410
410
1,050
410
410
600
1,600
380
60
600
620
2,650
650
50
9,900
1,980
7,920

Extended Renal Function Tests Package
Tests
Price
Serum Sodium
Serum Chloride
Micro Albumin
Serum Potassium
Serum Bicarbonate
Blood Urea Nitrogen
Creatinine Clearance (ml/min)
Urine D/R
Anion Gap (calculated value)
Serum Calcium
Serum Phosphorous
Serum Parathroid Hormone
Serum Uric Acid
Albumin / Creatinine Ratio Per 24 hours
Total
Discount
Package Price after discount (rounded to 10)

Osteoporosis Package
Tests
Calcium
Albumin
Corrected Total Calcium (calculated value)
Phosphorus
25 OH VIT D
PTH
ALP
NTX
Total
Discount
Package Price after discount (rounded to 10)

Package Code : HEPSP
Package Code :
ANEMP
Package Code : CARP
Package Code :ANTP
Package Code : HEMANE

Package Code : RFTP
Package Code : ERFTP
Package Code : OSTPP

Package Code : HSP
Package Code: EHSP
Package Code: MACP
Package Code: BHSP

Hepatitis Screening Package
Tests

Price

380
1,300
1,600
2,400
5,680
1,130
4,550

SGPT (ALT)
Hepatits B Surface Antigen
Hepatits B Surface Antibody
Anti HCV

Total
Discount
Package Price after discount (rounded to 10)

Price

Price

840
780
1,750
3,370
670
2,700

Microcytic Package
Tests
Serum Iron
TIBC
Serum Ferritin
Total
Discount

Package Price after discount (rounded to 10)

Cardiac Risk Package
Tests
Fasting Gulcose
HsCRP
Lipid Profile
Homocysteine

370
1,600
2,250
2,400
6,620
1,320
5,300
Total
Discount

Package Price after discount (rounded to 10)

Price

500
600
660
1,760
350
1,410

Price

700
1,200
380
1,300
2,400
1,750
2,150
900
10,780
1,610
9,170

Antenatal Package
Tests
CBC
Rscreen
Urine D/R
HBSAG
HCV
RUBIGG
RUBIGM
Anti-TPO

Hemolytic Panel
Tests

Total
Discount
Package Price after discount (rounded to 10)

Reticulocyte Count
LDH
Direct Coombs Test

Total
Discount
Package Price after discount (rounded to 10)

Discount On Special Packages Year 2015
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